myelopeptide 1 has been researched along with Ovarian Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bradley, A; Coerver, KA; Finegold, MJ; Mather, J; Matzuk, MM; Woodruff, TK | 1 |
| Boime, I; Byrne, MC; Kumar, TR; Matzuk, MM; Palapattu, G; Wang, P; Woodruff, TK | 1 |
2 other study(ies) available for myelopeptide 1 and Ovarian Neoplasms
| Article | Year |
|---|---|
Activin signaling through activin receptor type II causes the cachexia-like symptoms in inhibin-deficient mice.
Topics: Activin Receptors; Activins; Animals; Cachexia; Female; Inhibins; Liver; Male; Mice; Mice, Mutant Strains; Oligopeptides; Ovarian Neoplasms; Peptides; Receptors, Growth Factor; Sex Cord-Gonadal Stromal Tumors; Signal Transduction; Stomach; Testicular Neoplasms; Weight Loss | 1996 |
Transgenic models to study gonadotropin function: the role of follicle-stimulating hormone in gonadal growth and tumorigenesis.
Topics: Activins; Animals; Crosses, Genetic; Female; Follicle Stimulating Hormone; Gene Expression Regulation; Hemorrhage; Homozygote; Humans; Infertility, Female; Infertility, Male; Inhibins; Male; Metallothionein; Mice; Mice, Mutant Strains; Mice, Transgenic; Oligopeptides; Ovarian Neoplasms; Ovary; Peptides; Polycystic Ovary Syndrome; Seminal Vesicles; Steroids; Testicular Neoplasms; Urinary Tract; Wasting Syndrome | 1999 |